Jazz Pharmaceuticals plc Total Liabilities
Jazz Pharmaceuticals plc total liabilities. Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) has total liabilities worth €7.33 Billion EUR (≈ $8.57 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Jazz Pharmaceuticals plc (J7Z) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jazz Pharmaceuticals plc (2013–2025)
Total liabilities of Jazz Pharmaceuticals plc from 2013 to 2025. This chart illustrates how Jazz Pharmaceuticals plc's total liabilities have evolved over time, based on quarterly financial data. Explore Jazz Pharmaceuticals plc (J7Z) long-term investment share to see how much of total assets are deployed in long-term investments.
Jazz Pharmaceuticals plc Competitors by Total Liabilities
The table below lists competitors of Jazz Pharmaceuticals plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baxter International Inc
NYSE:BAX
|
USA | $13.61 Billion |
|
Semtech Corporation
NASDAQ:SMTC
|
USA | $898.17 Million |
|
Sartorius Aktiengesellschaft
XETRA:SRT3
|
Germany | €5.60 Billion |
|
Industrivarden AB ser. A
ST:INDU-A
|
Sweden | Skr7.00 Billion |
|
Krung Thai Bank Public Company Limited
F:NVPB
|
Germany | €3.35 Trillion |
|
The Phoenix Holdings Ltd.
TA:PHOE
|
Israel | ILA196.49 Billion |
|
The J. M. Smucker Company
NYSE:SJM
|
USA | $11.57 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Jazz Pharmaceuticals plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see J7Z total asset value.
Liquidity & Leverage Metrics
Jazz Pharmaceuticals plc Total Liabilities Ratios Explained
Jazz Pharmaceuticals plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jazz Pharmaceuticals plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jazz Pharmaceuticals plc (2013–2025)
The table below shows the annual total liabilities of Jazz Pharmaceuticals plc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.34 Billion ≈ $8.58 Billion |
-7.30% |
| 2024-12-31 | €7.92 Billion ≈ $9.26 Billion |
+3.42% |
| 2023-12-31 | €7.66 Billion ≈ $8.95 Billion |
-1.20% |
| 2022-12-31 | €7.75 Billion ≈ $9.06 Billion |
-7.01% |
| 2021-12-31 | €8.33 Billion ≈ $9.74 Billion |
+189.74% |
| 2020-12-31 | €2.88 Billion ≈ $3.36 Billion |
+18.46% |
| 2019-12-31 | €2.43 Billion ≈ $2.84 Billion |
-0.74% |
| 2018-12-31 | €2.45 Billion ≈ $2.86 Billion |
+1.47% |
| 2017-12-31 | €2.41 Billion ≈ $2.82 Billion |
-17.53% |
| 2016-12-31 | €2.92 Billion ≈ $3.42 Billion |
+68.57% |
| 2015-12-31 | €1.73 Billion ≈ $2.03 Billion |
-11.88% |
| 2014-12-31 | €1.97 Billion ≈ $2.30 Billion |
+108.74% |
| 2013-12-31 | €942.69 Million ≈ $1.10 Billion |
-- |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more